Novel Study Uncovers the Critical Role of ADAM10 Protein in the Development of Retinal Disorders

New research has found that the endothelial cell-specific A disintegrin and metalloproteinase domain-containing protein 10 (ADAM10) regulates abnormal blood vessel growth in the damaged retina, which can cause vision loss or impairment. The findings of the new study 打開新的分頁／視窗 in The American Journal of Pathology 打開新的分頁／視窗, published by Elsevier, have significant implications for understanding the pathophysiology of neovascular disorders like retinopathy of prematurity and diabetic retinopathy and provide a potential target for treatment.

ADAM10, a versatile protein involved in a wide range of cellular processes, particularly those related to the regulation of cell surface protein expression and intercellular communication, is known to have a physiological role in normal blood vessel formation. However, its role in proliferative retinopathies, in which abnormal blood vessel formation is the primary cause of vision loss and impairment, remains understudied.

The present study explored the role of endothelial cell-specific ADAM10 and its signaling on pathologic neovascularization within the retina. Using an endothelial-specific ADAM10 knockout mouse model (ADAM10^i∆EC), its goal was to uncover the molecular mechanisms underpinning ADAM10 participation in retinal neovascularization to provide fresh insights into potential therapeutic targets for retinal neovascular disorders.

Lead investigator Nikhlesh K. Singh, DVM, PhD, Integrative Biosciences Center and Department of Ophthalmology, Visual and Anatomical Sciences, School of Medicine, Wayne State University, says, “In this study, we discovered that ADAM10 activity was significantly elevated in the injured retina, and reducing ADAM10 levels or its activity notably slowed the growth, spread, movement, and tube formation of human retinal microvascular endothelial cells. Additionally, when we eliminated ADAM10 from the endothelial cells in mice, it substantially alleviated issues associated with retinal diseases, such as blood leakage from vessels, swelling, and the formation of new blood vessels.”

While investigating how ADAM10 influences abnormal blood vessel growth, the researchers found that ADAM10 regulates the levels of the protein Ephrin B2 in endothelial cells, and decreasing Ephrin B2 levels impacts the growth, movement, sprouting, and tube formation of human retinal endothelial cells. Furthermore, a significant increase in Ephrin B2 expression was observed in the damaged retina, and the removal of ADAM10 specifically from endothelial cells drastically reduced Ephrin B2 expression, indicating that ADAM10 plays a crucial role in the development of new blood vessels in the retina by regulating Ephrin B2 levels.

Pathologic retinal neovascularization is the primary cause of visual loss in diseases such as proliferative diabetic retinopathy, retinopathy of prematurity, central vein occlusion, and age-related macular degeneration. The extracellular matrix breakdown by metalloproteinase leads to vascular complications in various proliferative retinopathies. Most of the current therapeutic approaches for these diseases involve invasive and moderately effective surgical procedures, such as anti-VEGF (Vascular Endothelial Growth Factor) treatment.

Co-investigators Shivantika Bisen, MSc, and Purnima Gogoi, PhD, MVSc, Integrative Biosciences Center and Department of Ophthalmology, Visual and Anatomical Sciences, School of Medicine, Wayne State University, and Department of Medical Genetics, School of Medicine and Public Health, University of Wisconsin (PG), note, “Various clinical and experimental findings report that the use of anti-VEGF agents can result in neuronal damage, hypertension, myocardial infarction, stroke, and diabetes. Additionally, there are many patients who do not respond to anti-VEGF therapies. Our study shows that targeting ADAM10 or its downstream effectors, such as Ephrin B2, could offer novel strategies for managing or preventing retinal diseases characterized by pathologic neovascularization.”

Dr. Singh concludes, “The human body is a sophisticated and autonomous system, and we, as medical researchers, strive to comprehend the intricacies of its existence and functionality, continually fascinated by its self-sufficiency and resilience. Our study has significant implications for understanding the pathophysiology of hypoxic and/or ischemic retinal diseases and highlights potential therapeutic targets, paving the way for novel treatment strategies beyond current anti-VEGF therapies.”

Notes for editors

The article is “A Disintegrin and Metalloproteinase 10 Regulates Ephrin B2–Mediated Endothelial Cell Sprouting and Ischemic Retinopathy,” by Shivantika Bisen, Purnima Gogoi, Anamika Sharma, Chandra S. Mukhopadhyay, and Nikhlesh K. Singh (https://doi.org/10.1016/j.ajpath.2025.03.007 打開新的分頁／視窗). It appears in The American Journal of Pathology, volume 195, issue 7 (July 2025), published by Elsevier.

The article is openly available for 90 days at https://ajp.amjpathol.org/article/S0002-9440(25)00114-2/fulltext 打開新的分頁／視窗.

Full text of the article is also available to credentialed journalists upon request. Contact Eileen Leahy at +1 732 406 1313 or [email protected] 打開新的分頁／視窗 to request a PDF of the article or more information. To reach the study’s authors, contact Julie O'Connor, Director of Research Communications, Division of Research & Innovation, Wayne State University, at +1 313 577 8845 or [email protected] 打開新的分頁／視窗.

The study was supported by National Institutes of Health, National Eye Institute, EY029709 and P30EY04068, and a Research to Prevent Blindness unrestricted grant (Kresge Eye Institute).

About The American Journal of Pathology

The American Journal of Pathology 打開新的分頁／視窗, official journal of the American Society for Investigative Pathology 打開新的分頁／視窗, published by Elsevier, seeks high-quality original research reports, reviews, and commentaries related to the molecular and cellular basis of disease. The editors will consider basic, translational, and clinical investigations that directly address mechanisms of pathogenesis or provide a foundation for future mechanistic inquiries. Examples of such foundational investigations include data mining, identification of biomarkers, molecular pathology, and discovery research. High priority is given to studies of human disease and relevant experimental models using molecular, cellular, and organismal approaches. ajp.amjpathol.org 打開新的分頁／視窗

關於 Elsevier

身為科學資訊與分析的全球領導者，Elsevier 協助研究人員與醫療照護專業人員推動科學發展，改善醫療成果，造福社會。我們以可信賴、以實證為基礎的內容和先進的 AI 數位技術為基礎，透過創新的解決方案促進洞察力和關鍵決策。

140 多年來，我們一直為研究和醫療保健界的工作提供支援。我們全球 9,500 名員工，包括 2,300 名技術人員，致力於支援研究人員、圖書館館長、學術領袖、資金提供者、政府、研發密集型公司、醫生、護士、未來醫療保健專業人員和教育工作者的重要工作。我們的 2,900 種科學期刊和經典參考工具書包括其領域中最重要的書籍，包括 Cell Press、The Lancet 和 Gray's Anatomy。 我們與愛思唯爾基金會 (Elsevier Foundation 打開新的分頁／視窗) 合作，與我們服務的社群攜手合作，在發展中國家和世界各地的科學、研究和醫療保健領域推動包容性和多樣性。 Elsevier 是 RELX 打開新的分頁／視窗 的一部分，RELX 打開新的分頁／視窗 是一家為專業和商業客戶提供以資訊為基礎的分析和決策工具的全球供應商。有關我們的工作、數位解決方案和內容的更多資訊，請造訪 www.elsevier.com 。